RETRACTED ARTICLE: Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness

  • Yoshitaka Fujii
  • Hidenori Toyooka
  • Hiroyoshi Tanaka
Reports of Investigation

Abstract

Purpose

This randomized, placebo-controlled, double-blind study was to evaluate the effects of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing postoperative nausea and vomiting in 110 patients with (n = 50) and without (n = 60) a history of motion sickness undergoing general anaesthesia for major gynaecological surgery.

Methods

The patients received a single dose of either granisetron (40 μg · kg−1) or placebo (saline) iv over 2–5 min immediately before induction of anaesthesia. Postoperatively, during the first 24 hr after anaesthesia, the frequencies of nausea and vomiting were recorded.

Results

Except for a positive history of motion sickness, the treatment groups were similar for patient characteristics, types of surgery, anaesthetics administered and opioids given. Postoperatively, the frequency of nausea was 44% and 16% after administration of placebo and granisetron in patients with motion sickness, and was 30% and 7% in patients without it, respectively; the corresponding frequencies of vomiting were 28%, 8%, 13% and 3%. The incidence of adverse events postoperatively were not different among the groups.

Conclusion

These results suggest that preoperative prophylactic administration of granisetron is effective and safe for preventing postoperative nausea and vomiting in patients with motion sickness as well as in patients without it.

Key words

complications: nausea, vomiting surgery: gynaecological vomiting: antiemetics, granisetron, incidence, motion sickness, nausea, postoperative 

Résumé

Objectif

Cette étude randomisée, contrôlée avec placebo et en double aveugle visait à évaluer les effets du granisetron, un antagoniste des récepteurs de type 3 de la 5-hydroxytriptamine, sur la prévention des nausées et des vomissements postopératoires chez 100 patientes avec (n − 50) ou sans (n = 60) antécédents de mal des transports subissant une anesthésie générale pour un chirurgie gynécologique majeure.

Méthodes

Les patientes ont reçu en une seule dose iv soit du granisetron (40 μg · kg−1), soit du soluté physiologique, en 2–5 min immédiatement avant l’induction de l’anesthésie. La fréquence des nausées et des vomissements a été enregistrée à la période postopératoire.

Résultats

À l’exception des antécédents de mal des transports, les caractéristiques des patientes, le type d’intervention, les anesthésiques et les morphiniques administrés étaient indentiques. En postopératoire, la fréquence des nausées a été de 44% et de 16% respectivement pour le placebo et le granisetron chez les patientes souffrant de mal des transports et de 30% et de 7% chez celles qui n’en souffraient pas: les fréquences correspondantes pour les vomissements ont été de 28%, 8%, 13% et de 3%. L’incidence des complications postopératoires n’a pas différé entre les groupes.

Conclusion

Ces résultats suggèrent que l’administration prophylactique préopératoire de granisetron peut prévenir efficacement et en toute sécurité les nausées et tes vomissements postopératoires chez les patientes qui souffrent du mal des transport comme chez celles qui n ’en souffrent pas.

References

  1. 1.
    McKenzie R, Wadhwa RK, Uy NTL, et al. Antiemetic effectiveness of intramuscular hydroxyzinc compared with intramuscular droperidol. Anesth Analg 1981; 60: 783–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Watcha MF, White RF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Kamath B, Curran J, Hawkey C, et al. Anaesthesia, movement and emesis. Br J Anaesth 1990; 64: 728–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Bermudez J, Boyle EA, Miner WD, Sanger GJ. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41: 291–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth 1994; 41: 794–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Leeser J, Lip H. Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. Anesth Analg 1991; 72: 751–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Fujii Y, Tanaka H, Toyooka H. Prevention of postoperative nausea and vomiting with granisetron: a randomized, double-blind comparison with droperidol. Can J Anaesth 1995; 42: 852–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs, (I). Optimal dose-finding study. (Japanese) Journal of Clinical and Therapeutic Medicine 1990;6:49–61.Google Scholar
  11. 11.
    Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. Anesth Analg 1979; 58: 396–400.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1996

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Hidenori Toyooka
    • 1
  • Hiroyoshi Tanaka
    • 2
  1. 1.Department of Anaesthesiology and Critical Care MedicineTokyo Medical and Dental University School of MedicineTokyoJapan
  2. 2.Department of AnaesthesiologyToride Kyodo General HospitalIbarakiJapan

Personalised recommendations